{
    "Trade/Device Name(s)": [
        "DreaMed Advisor Pro"
    ],
    "Submitter Information": "DreaMed Diabetes Ltd.",
    "510(k) Number": "K191370",
    "Predicate Device Reference 510(k) Number(s)": [
        "DEN170043"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "QCC"
    ],
    "Summary Letter Date": "July 18, 2019",
    "Summary Letter Received Date": "May 22, 2019",
    "Submission Date": "May 20, 2019",
    "Regulation Number(s)": [
        "21 CFR 862.1358"
    ],
    "Regulation Name(s)": [
        "Insulin therapy adjustment device"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "endocrine"
    ],
    "Analyte(s)": [
        "Glucose",
        "Insulin"
    ],
    "Specimen Type(s)": [
        "Capillary blood (for SMBG)",
        "Interstitial fluid (CGM)"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Insulin pump",
        "Continuous glucose monitoring (CGM) system",
        "Blood glucose meter",
        "Qualified Diabetes Management System (DMS)"
    ],
    "Method(s)/Technology(ies)": [
        "Software algorithm",
        "Decision-support software"
    ],
    "Methodologies": [
        "Data analysis",
        "Recommendation engine"
    ],
    "Submission Type(s)": [
        "Software",
        "Decision-support software"
    ],
    "Document Summary": "FDA 510(k) summary for DreaMed Advisor Pro decision-support software for insulin therapy adjustment in type 1 diabetes using insulin pump, CGM, and SMBG data.",
    "Indications for Use Summary": "Assists healthcare professionals in managing patients aged 6-65 with type 1 diabetes using insulin pumps and CGM/SMBG, by generating recommendations for insulin pump settings (basal rate, carbohydrate ratio, correction factor) without considering full clinical status; does not replace clinical judgment.",
    "fda_folder": "Clinical Chemistry"
}